Accelerating enrollment for life-saving treatments in infectious disease trials
Bringing vaccines to market isn’t just about checking a box in drug development – it’s about delivering solutions to infectious diseases that are impacting the entire world.
1nHealth takes full ownership of the enrollment process across this vitally important therapeutic area so your team can focus on what they do best—delivering vaccines and infectious disease therapies that make a difference.
0
Patients enrolled
0
Studies completed
0
Sites coordinated
Our difference
Infectious disease clinical trials require reliable results from a diverse participant pool
Infectious disease and vaccine trials demand patient recruitment that is reflective of real-world populations. Enrollment must be diverse across socioeconomic, cultural, and geographic demographics.
Patient data has to be collected accurately and ethically, and real-time results help you make informed decisions across the entire recruitment timeline.
At 1nHealth, we own the enrollment process so that you can focus on delivering results for your innovative life-saving solutions.
Your trial is urgent and your patient recruitment should be too
- You rely on experts who understand complex I/E criteria and have experience with complex symptoms to ensure high-quality referrals
- You need a recruitment partner who understands how every step of the funnel works together to deliver results on time and under budget
- You demand diverse representation, especially within conditions that disproportionately affect specific populations
- You expect quick and efficient site support when trials are enrolling extremely large patient populations globally
Our expertise
Shingles
Shingles is a reactivation of the varicella-zoster virus (VZV), typically in individuals who had chickenpox earlier in life.
It primarily affects older adults, with the risk increasing significantly after age 50. Clinical manifestations include a painful, unilateral rash with blisters, often accompanied by postherpetic neuralgia (PHN), a debilitating chronic pain condition.
The pathophysiology involves VZV latency in dorsal root ganglia and immune system decline with age. Vaccination is the most effective prevention strategy.
COVID
COVID-19, caused by the SARS-CoV-2 virus, emerged as a global pandemic in late 2019, leading to significant morbidity, mortality, and healthcare disruption.
The virus primarily spreads through respiratory droplets and affects the respiratory system, with symptoms ranging from mild cold-like signs to severe pneumonia and acute respiratory distress syndrome (ARDS). Risk factors include older age, comorbidities, and immunocompromised status.
Ongoing research focuses on variants of concern, vaccine efficacy, long-term immunity, treatment strategies, and public health interventions.
Rhinoviruses
The common cold, primarily caused by rhinoviruses, is one of the most prevalent viral infections, with individuals experiencing multiple episodes per year.
Symptoms include nasal congestion, sore throat, cough, sneezing, and mild systemic effects such as fatigue and low-grade fever. The disease is self-limiting but highly contagious, spreading through respiratory droplets and direct contact.
While the common cold typically resolves within one to two weeks, it is a major cause of missed work and school.
Our success
"1nHealth's ability to apply their skills and knowledge across many therapeutic areas makes them a one-stop shop for any enrollment campaign."
Sponsor
COVID-19 Registry
Atrial Fibrillation
Hover to reveal top creative
Shingles Vaccine
Atopic Dermatitis
Chronic Venous Ineffiency
Hover to reveal top creative
Our experience across other therapeutic areas
Your next trial is thoughtful, complex, and different. Your patient recruitment should be too.
From kick-off to last patient in, 1nHealth builds a reliable source of referred enrollments through proven recruitment programs and high-touch patient engagement.
Click each area to learn more.
